Literature DB >> 17991264

The use of intranasal midazolam in the treatment of paediatric dental patients.

F Gilchrist1, A M Cairns, J A Leitch.   

Abstract

The aim of this study was to assess the use of intranasal midazolam in paediatric dental patients requiring extractions or simple surgical procedures who may otherwise have required a general anaesthetic. Twenty children aged between 2-9 years who required simple surgical procedures were given 0.25 mg.kg(-1) midazolam, administered using a MAD (Mucosal Atomization Device; Wolfe Tory Medical Inc., Salt Lake City, UT, USA). Compliance with the full dose was achieved in 14 patients, 13 of whom completed the treatment. One of two patients who allowed only partial administration completed the treatment and three patients did not comply. The mean time to starting treatment was 13 min (range 6-25 min) and patients were discharged after a mean of 46 min (range 25-67 min). Physiological parameters remained stable throughout with no clinically significant episodes of desaturation. One patient vomited at home postoperatively. Midazolam in a dose of 0.25 mg.kg(-1) administered intranasally provided adequate anxiolysis for the majority of children, allowing them to complete their treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17991264     DOI: 10.1111/j.1365-2044.2007.05260.x

Source DB:  PubMed          Journal:  Anaesthesia        ISSN: 0003-2409            Impact factor:   6.955


  7 in total

1.  Trigeminal pathways deliver a low molecular weight drug from the nose to the brain and orofacial structures.

Authors:  Neil J Johnson; Leah R Hanson; William H Frey
Journal:  Mol Pharm       Date:  2010-06-07       Impact factor: 4.939

2.  Safety and physiologic effects of intranasal midazolam and nitrous oxide inhalation based sedation in children visiting Saveetha Dental College and Hospitals, India.

Authors:  Neethu Ann Preethy; Sujatha Somasundaram
Journal:  Bioinformation       Date:  2022-01-31

3.  Comparison of the Sedative Effect of Inhaled Nitrous Oxide and Intranasal Midazolam in Behavior Management and Pain Perception of Pediatric Patients: A Split-mouth Randomized Controlled Clinical Trial.

Authors:  Navaneetha Krishnan Srinivasan; Pradeep Karunagaran; Veerale Panchal; Emg Subramanian
Journal:  Int J Clin Pediatr Dent       Date:  2021

4.  A randomised, double-blind controlled trial of intranasal midazolam for the palliation of dyspnoea in patients with life-limiting disease.

Authors:  Janet Hardy; Clare Randall; Eve Pinkerton; Christopher Flatley; Kristen Gibbons; Simon Allan
Journal:  Support Care Cancer       Date:  2016-02-18       Impact factor: 3.603

5.  Comparative Analysis of Intravenous Midazolam with Nasal Spray for Conscious Sedation in Minor Oral and Maxillofacial Surgeries.

Authors:  Ramesh Kunusoth; Gururam Tej; Kranti Kiran Reddy Ealla; Pavan Kumar Kathuroju; Anusha Ayyagari; Aditya Mohan Alwala
Journal:  J Pharm Bioallied Sci       Date:  2019-02

6.  Pharmacokinetics and pharmacodynamics of intranasal remimazolam-a randomized controlled clinical trial.

Authors:  Marija Pesic; Frank Schippers; Rob Saunders; Lyn Webster; Martin Donsbach; Thomas Stoehr
Journal:  Eur J Clin Pharmacol       Date:  2020-09-04       Impact factor: 2.953

7.  Unique challenges in pediatric anesthesia created by COVID-19.

Authors:  Nan Gai; Jason T Maynes; Kazuyoshi Aoyama
Journal:  J Anesth       Date:  2020-08-07       Impact factor: 2.078

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.